Ikena Oncology (IKNA) Q4 2024 earnings summary

Executive summary

• Entered into a merger agreement with Inmagene Biopharmaceuticals in December 2024; closing expected mid-2025, subject to shareholder approval and other conditions.

• Discontinued development of IK-930 and focused resources on IK-595, a dual MEK-RAF inhibitor in Phase 1 clinical trials for RAS/RAF mutant cancers.

• Workforce reduced by approximately 88% in 2024 through two restructurings to conserve capital and align with strategic priorities.

• No products approved for sale; no revenue from product sales; continued to divest and out-license non-core assets.

• Net losses narrowed to $49.2 million in 2024 from $68.2 million in 2023; accumulated deficit reached $331.6 million.

Financial highlights

• Net loss for 2024 was $49.2 million, a 28% improvement from $68.2 million in 2023.

• Research and development expenses decreased 48% year-over-year to $30.9 million, reflecting program prioritization and headcount reductions.

• General and administrative expenses declined 5% to $23.7 million, mainly due to lower personnel and insurance costs.

• Cash, cash equivalents, and marketable securities totaled $124.4 million as of December 31, 2024.

• No collaboration revenue recognized in 2024; all prior deferred revenue fully recognized by end of 2023.

Outlook and guidance

• Merger with Inmagene expected to close mid-2025; combined company to focus on Inmagene’s lead asset, IMG-007, in immunology and inflammation.

• If merger is not completed, board may pursue dissolution and liquidation; cash runway expected to last at least 12 months from filing date.

• Ongoing strategic review for legacy programs, including potential out-licensing or sale.